
|Articles|September 1, 2002
- Psychiatric Times Vol 19 No 9
- Volume 19
- Issue 9
Father Fear
When she asks me to massage the ache in her knuckles,
Advertisement
When she asks me to massage
the ache in her knuckles,
I recall women I have touched
whose hands twisted
like apricot limbs
in their search for light.
I've never asked how
they hold a fork, play piano,
or stroke a lover's hair,
and when I rub my daughter's bones
with the soft pads of my fingertips
it is like wishing on a magic lamp:
Please, not Lupus,
not steroids or morphine or wheelchairs.
I've seen apricots in my orchard
blossom too soon,
so fragrant in early April
killed by hard frost in May.
Articles in this issue
about 24 years ago
End of Storyabout 24 years ago
Supreme Court Decision Raises New Ethical Questions for Psychiatryabout 24 years ago
Help for Psychiatrists Who Lose a Patient to Suicideabout 24 years ago
Antidepressants Versus Placebos: Meaningful Advantages Are Lackingabout 24 years ago
Optimizing ADHD Treatmentabout 24 years ago
Depressive Disorders in Adolescents: Challenges in Diagnosisabout 24 years ago
Behavioral Issues in Pediatric Epilepsyabout 24 years ago
Catatonia in Adolescents and Childrenabout 24 years ago
Small Effects Are Not Trivial From a Public Health PerspectiveAdvertisement
Related to this article

Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.

Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.

Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.

Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.

Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.

Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.

FDA clears Motivista, a prescription smartphone digital therapeutic, to reduce negative symptoms of schizophrenia—supported by phase 3 results and strong patient engagement.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
3
Clozapine Remains Underused After REMS Elimination: A Conversation With Jose Rubio, MD, PhD
4
Phase 1 Clinical Studies Completed: NTX-253 for the Treatment of Schizophrenia
5

